Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature.
about
Cancer-treatment-induced neurotoxicity--focus on newer treatmentsSmall molecules in the treatment of systemic lupus erythematosusBortezomib-induced painful peripheral neuropathy: an electrophysiological, behavioral, morphological and mechanistic study in the mouseThe choice of regimens based on bortezomib for patients with newly diagnosed multiple myelomaDrug interaction between itraconazole and bortezomib: exacerbation of peripheral neuropathy and thrombocytopenia induced by bortezomib.Bortezomib plus thalidomide for newly diagnosed multiple myeloma in China.Combination of IFN-α/Gm-CSF as a Maintenance Therapy for Multiple Myeloma Patients After Autologous Stem Cell Transplantation (ASCT): A Prospective Phase II Study.Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations.Dorsal Column Degeneration after Bortezomib Therapy in a Patient with Multiple Myeloma.Fatal Cytomegalovirus Pneumonia and Associated Herpes Virus Infection in a Relapsed/Refractory Multiple Myeloma Patient Treated with Bortezomib plus Dexamethasone.Bortezomib in the management of multiple myeloma.Proteasome inhibitors in the treatment of multiple myelomaThe use of novel agents in the treatment of relapsed and refractory multiple myelomaAcupuncture treatment for bortezomib-induced peripheral neuropathy: a case reportA pilot study of acupuncture in treating bortezomib-induced peripheral neuropathy in patients with multiple myeloma.Beneficial effect of novel proteasome inhibitors in murine lupus via dual inhibition of type I interferon and autoantibody-secreting cells.Pharmacologic screens reveal metformin that suppresses GRP78-dependent autophagy to enhance the anti-myeloma effect of bortezomib.Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping.Neurotoxicity of biologically targeted agents in pediatric cancer trialsSubclinical pretreatment sensory deficits appear to predict the development of pain and numbness in patients with multiple myeloma undergoing chemotherapy.Characteristics of bortezomib- and thalidomide-induced peripheral neuropathy.Phytohemagglutinin-induced IL2 mRNA in whole blood can predict bortezomib-induced peripheral neuropathy for multiple myeloma patients.Clinical challenges: Myeloma and concomitant type 2 diabetes.Clinical challenges: myeloma and concomitant type 2 diabetesA perspective on B-cell-targeting therapy for SLE.Bortezomib-induced painful neuropathy in patients with multiple myeloma.CUL4A ubiquitin ligase: a promising drug target for cancer and other human diseasesA common variant within the HNF1B gene is associated with overall survival of multiple myeloma patients: results from the IMMEnSE consortium and meta-analysis.Long-Term Effects, Pathophysiological Mechanisms, and Risk Factors of Chemotherapy-Induced Peripheral Neuropathies: A Comprehensive Literature Review.Falls in persons with chemotherapy-induced peripheral neuropathyPeripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies.Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma.Guidelines for supportive care in multiple myeloma 2011.New Treatment Approaches for Older Adults with Multiple Myeloma.Drug-induced peripheral neuropathy.Chemotherapy-induced polyneuropathy: major agents and assessment by questionnaires.Chemotherapy-induced peripheral neuropathies in hematological malignancies.Therapy-related peripheral neuropathy in multiple myeloma patients.A comparison of bortezomib, cyclophosphamide, and dexamethasone (Vel-CD) chemotherapy without and with thalidomide (Vel-CTD) for the treatment of relapsed or refractory multiple myeloma.Modulation of NF-κB Signaling as a Therapeutic Target in Autoimmunity.
P2860
Q26782604-3B23B596-9DC9-4489-88D3-64E44DA9EF03Q27010090-C5DE3FD7-7C3A-4261-955C-A6F37F3B4DA8Q28533426-A2056DAE-22D8-4FC5-8EC1-752A75A03D80Q28539605-25BFF404-0826-455F-AF4D-628CBCA20738Q33390377-90CD1951-9569-4CEC-AD76-6608A0D21D81Q33391566-258B3F83-92C0-4568-8200-FF72CA88842FQ33393257-3EDD1552-1FBC-4F5D-B547-39C1386E2DDBQ33632270-0273FBC0-E977-4E18-9A48-BC050159B12BQ34038037-F4BFBD12-5D54-4CBA-8F78-DE997FC0CDACQ34054816-DF0DBE1B-A581-4DDE-838E-AC54CF1675E8Q34418462-90B24D99-37A4-4027-BA57-B030858C92C4Q34611676-1780A3E9-4CE2-4785-BC47-DB0E4D797BE3Q35097319-5FBC962B-B1FC-4072-B63D-119C3E7FD9ABQ35428713-2BD6B904-017E-45B7-97D1-85AD98D1EDE4Q36037229-063E2F9B-690B-4C22-9A01-E03073D812C0Q36096756-D740F12A-9DDC-4283-8E3A-C6CE021ECD86Q36254571-74A8BD75-97CA-4D16-BA79-3722F09AD9EDQ36697556-E09C21AA-F6E8-48A7-9C7B-B8DAB65D1862Q36766221-AB99403C-0342-4AA9-B008-FEAF716D5276Q36893299-08075F65-E8A8-41C1-AAFA-211602FB8AE0Q37090630-832C481A-4840-4098-9F07-C6DF16D51706Q37275721-648CC05E-C36A-4EDC-9FD9-8C2B76522E71Q37467309-B77804B5-0FE2-467E-81BA-A677DB3E3536Q37552667-13FD66DB-8DD2-4D8D-B3C3-7D4616913D91Q37577571-76BF771D-333A-475F-9F5D-30F5D897CD11Q37601865-D362A365-3C9A-4EEF-A4B7-7E91D2ED24BFQ37609233-9CC6E503-27C9-4C18-8CA2-FC8CF83D6E2CQ37644812-5A664BCB-66AB-49D7-8834-B01D656D4526Q37662576-0802CA77-89D6-427A-9621-8F6A232DB51DQ37744274-CCB1D572-69CF-4D39-B56D-D8673546970FQ37760210-6441042C-04E3-4259-A062-A77077DCD3F6Q37842346-AB39F2D8-099F-429F-8BAE-9042EFCCDA17Q37868637-83868BB0-82C8-4FB3-A33D-5A229186A6C2Q38048281-9D6F3BBE-61C1-4DAC-A214-08634A2ACDC8Q38208565-94BF23E1-F09F-41D6-8952-A1A5D62EAD4FQ38209390-2CEF1027-9BAF-4E21-9347-EE4FEBFA953BQ38261204-C887F2C2-940D-4C68-9286-4B1A7CDDC44AQ38268525-0D9FAE32-9A8B-4EF7-A274-8B2397F0DE7FQ38465618-93F3DA4E-475F-4C30-A08E-1AE523FC1DB4Q38644746-4A054B7C-2334-4B62-ADFF-83C6FF37938A
P2860
Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Neurotoxicity of bortezomib th ...... and review of the literature.
@en
type
label
Neurotoxicity of bortezomib th ...... and review of the literature.
@en
prefLabel
Neurotoxicity of bortezomib th ...... and review of the literature.
@en
P2093
P356
P1433
P1476
Neurotoxicity of bortezomib th ...... and review of the literature.
@en
P2093
Aaron P Rapoport
Ashraf Badros
Gorgon Akpek
Jay S Dalal
Jennifer Thompson
Meyer Heyman
Olga Goloubeva
Robert G Fenton
P304
P356
10.1002/CNCR.22921
P407
P577
2007-09-01T00:00:00Z